Grace Therapeutics, Inc.
Price Action
Technical Summary
EMERGING TRENDGrace Therapeutics, Inc. shows underlying uptrend characteristics but has temporarily lost support at the 50-day moving average. Relative strength is weak (RS Rating: 9), showing significant lag compared to the market leaders. Earnings growth of 61% provides fundamental context to the price action. Investors should exercise caution due to high volatility (72% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $3.18 | -29.25% | BELOW |
| 50 SMA | $3.81 | -40.88% | BELOW |
| 100 SMA | $3.72 | -39.44% | BELOW |
| 150 SMA | $3.52 | -36.07% | BELOW |
| 200 SMA | $3.42 | -34.17% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is GRCE in an uptrend right now?
GRCE has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is GRCE overbought or oversold?
GRCE's RSI (14) is 33. The stock is in neutral territory, neither overbought nor oversold.
Is GRCE outperforming the market?
GRCE has a Relative Strength (RS) Rating of 9 out of 99. GRCE is currently lagging the broader market.
Where is GRCE in its 52-week range?
GRCE is trading at $2.25, which is 43% of its 52-week high ($5.18) and 14% above its 52-week low ($1.79).
How volatile is GRCE?
GRCE has a Beta of 0.87 and 52-week volatility of 72%. It's less volatile than the S&P 500 - generally more stable.